Today, there is still a large number of GLP-1R agonists entering clinical trials, which will lead to a big explosion in the future, so let's wait and see together
(laughs) David Kellner, MD: I would say the most common side effects with these medications are gastrointestinal, so nausea, diarrhea, constipation, acid reflux, and this is especially during dose increases
That triple agonism is generating intense interest in pre-clinical metabolic-research circles, where investigators are comparing it head-to-head against the dual agonist Tirzepatide and the GLP-1 mono-agonist Semaglutide
Trapp, S., & Brierley, D
The informal term "GLP-3" refers to a new triple-agonist drug that targets three hormones: GLP-1, GIP (glucose-dependent insulinotropic polypeptide, another naturally occurring hormone released by the gut after eating) and glucagon receptors
The Breaking Point "I wasn't happy with the way I looked, the way I felt, and my blood work was not good," Juls recalls about her state in spring 2022